Autolus Therapeutics plc (ADR)
General ticker "AUTL" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $520.8M (TTM average)
Autolus Therapeutics plc (ADR) follows the US Stock Market performance with the rate: 9.2%.
Estimated limits based on current volatility of 4.6%: low 1.39$, high 1.52$
Factors to consider:
- Total employees count: 463 as of 2023
- US accounted for 79.6% of revenue in the fiscal year ended 2023-12-31
- Top business risk factors: Operational and conduct risks, Limited operating history, Labor/talent shortage/retention, Geopolitical risks, Currency fluctuations
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.22$, 3.19$]
- 2025-12-31 to 2026-12-31 estimated range: [1.02$, 2.62$]
Financial Metrics affecting the AUTL estimates:
- Positive: with PPE of -2.6 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -35.72 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: 41.86 < Shareholder equity ratio, % of 54.59 <= 63.39
- Positive: Interest expense per share per price, % of 1.61 <= 3.41
Short-term AUTL quotes
Long-term AUTL plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $5.84MM | $0.00MM | $9.90MM |
| Operating Expenses | $149.25MM | $179.70MM | $251.32MM |
| Operating Income | $-143.41MM | $-179.70MM | $-241.43MM |
| Non-Operating Income | $-5.16MM | $-28.70MM | $22.29MM |
| Interest Expense | $8.90MM | $45.07MM | $9.29MM |
| R&D Expense | $117.35MM | $130.48MM | $138.44MM |
| Income(Loss) | $-148.57MM | $-208.40MM | $-219.13MM |
| Taxes | $0.27MM | $-0.02MM | $1.53MM |
| Profit(Loss)* | $-148.84MM | $-208.38MM | $-220.66MM |
| Stockholders Equity | $298.67MM | $111.47MM | $427.32MM |
| Inventory | $0.00MM | $0.00MM | $4.14MM |
| Assets | $490.27MM | $375.38MM | $782.73MM |
| Operating Cash Flow | $-112.31MM | $-145.59MM | $-206.27MM |
| Capital expenditure | $10.84MM | $10.99MM | $34.82MM |
| Investing Cash Flow | $-10.84MM | $-10.99MM | $-394.55MM |
| Financing Cash Flow | $223.61MM | $-0.88MM | $589.55MM |
| Earnings Per Share** | $-1.57 | $-1.20 | $-0.86 |
| Ordinary share to ADR | 1.00x | 1.00x | 1.00x |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.